Quanterix Narrows 2026 Revenue Guidance Amid Q3 Growth and New Medicaid Reimbursement
Quanterix (QTRX) reported third-quarter results that exceeded top-line expectations, achieving a sequential revenue growth of 6.3%. CEO Everett Cunningham noted broad improvements across the business during the earnings call. The company has narrowed its 2026 revenue outlook to a range of $142 million to $146 million. This guidance comes alongside significant regulatory developments for its LucentAD product, as Florida Medicaid has established a reimbursement rate of $484.
Tickers: $QTRX
Topics: earnings quarterly results revenue growth
Read the full article at Seeking Alpha
Part of the story Artmarket.com Announces Q3 2026 Revenue Growth and Upcoming Launch of AI-Driven Visual Search Tool (35 articles)